<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D35206BF-C720-4D00-AE75-B4D653826FCD"><gtr:id>D35206BF-C720-4D00-AE75-B4D653826FCD</gtr:id><gtr:firstName>Grace</gtr:firstName><gtr:surname>Megarrell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601422"><gtr:id>67A7D7B5-6947-47B2-AFB6-3922BFFA83B2</gtr:id><gtr:title>The role of IL-33 in the innate and adaptive immune responses in asthma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0601422</gtr:grantReference><gtr:abstractText>Asthma affects over 5 million people in the U.K and the incidence is increasing. This disorder is characterised by breathlessness and cough with occasional deteriorations in symptoms, often requiring hospitalisation. Asthma is caused when the body?s immune system responds inappropriately within the lungs. Many different types of immune cells are involved in asthma and these cells communicate with each other by releasing messenger molecules. When these messages are too strong, this can lead to inflammation and subsequent asthma. 
Recent work suggests that a new messenger molecule called IL-33 causes worsening inflammation in the airways and may act on a number of different immune cells to cause damage. I intend to investigate how IL-33 works and it?s role in asthma by studying a mouse model and examining samples from human asthmatics. 
Developing new treatments for asthma is important as current treatments options are limited and can often carry undesirable side effects. In addition to improving our understanding of this significant condition, studying IL-33 could lead to a novel target for new treatments acting to block it?s effects.</gtr:abstractText><gtr:technicalSummary>Asthma continues to be a cause of significant morbidity and mortality and prove a considerable economic and social burden. Airway inflammation is key in the pathogenesis of asthma and hence, corticosteroids remain the most important anti-inflammatory treatment. Therefore, there is a drive to develop novel, more specific and safer therapies. 
Asthma pathophysiology involves complex interactions between a diverse group of cells in the innate and adaptive immune systems and is mediated by a range of cytokines and inflammatory mediators. Interleukin (IL)-33 is a recently discovered pro-inflammatory cytokine which signals through the receptor ST2L. My preliminary data show that IL-33 administered intranasally (i.n.) to mice caused severe airway inflammation as demonstrated by increased eosinophilia in the bronchoalveolar lavage fluid (BALF). Furthermore, IL-33 administered to antigen-specific murine asthma model, worsened the inflammation. These results have led to my hypothesis that IL-33 exacerbates the innate and adaptive arms of the immune responses in airway inflammation and asthma.
I therefore propose to (i) characterize the cell types induced by IL-33 in airways inflammation in mice, (ii) determine the contribution of IL-33 to chronic T cell-mediated airway inflammation in OVA-induced murine asthma, and (iii) investigate the presence of IL-33 in different grades of asthma.
Using an in vivo mouse model of airway inflammation, IL-33 will be introduced i.n. at various time points. Cell characterization in the BALF will be analysed and quantified using flow cytometry. Immunhistochemistry of lung tissues will be performed to further assess the type and extent of cellular infiltration in the inflammatory site. To assess the contribution of the adaptive immune system to airway inflammation, similar analysis on the BALF will be performed using RAG-/- mice which completely lack B and T cells. Subsequent transfer of OVA-specific Th2 cells to RAG-/- recipients preceding intranasal IL-33 administration will identify the contribution of the Th2 cells to the inflammatory response to IL-33. In addition, the consequences of neutralising IL-33 by anti-IL-33 antibody administration will be assessed in a well-established OVA-specific murine model using wild type and IL-33-/- mice. Finally, the presence of IL-33 will be sought in sputum and peripheral blood samples from different grades of asthmatics using quantitative PCR and ELISA. These experiments should demonstrate the relationship between IL-33 and clinical asthma.
Thus understanding how IL-33 functions and the effects of IL-33 neutralisation on airway inflammation, may lead to the development of novel therapeutic strategies against inflammation in general and asthma in particular.</gtr:technicalSummary><gtr:fund><gtr:end>2011-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>195752</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1B32FE5E-7C05-46B9-8042-AAFFE4E62463</gtr:id><gtr:title>The IL-33/ST2 pathway controls coxsackievirus B5-induced experimental pancreatitis.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d0729b1b2fbb5a4d15e19c73abc497f"><gtr:id>3d0729b1b2fbb5a4d15e19c73abc497f</gtr:id><gtr:otherNames>Sesti-Costa R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14749_29_23733876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D9DDB15-C7DD-4588-A1AF-90119E79E4A9</gtr:id><gtr:title>IL-33 attenuates EAE by suppressing IL-17 and IFN-? production and inducing alternatively activated macrophages.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2a2fc1758d2867fc19fb4fd882fa28f"><gtr:id>f2a2fc1758d2867fc19fb4fd882fa28f</gtr:id><gtr:otherNames>Jiang HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14749_29_22585447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E23F296-BF66-40F7-A4B3-7197F7363035</gtr:id><gtr:title>Disease-associated functions of IL-33: the new kid in the IL-1 family.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d903f48e79964a5d02e098b694a592d"><gtr:id>0d903f48e79964a5d02e098b694a592d</gtr:id><gtr:otherNames>Liew FY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1474-1733</gtr:issn><gtr:outcomeId>GYHdrvv7xcD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75E56B92-06F3-4264-B9E9-6022C189E957</gtr:id><gtr:title>IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46e2ecdbdcf081c5e7884ac05702bb5"><gtr:id>c46e2ecdbdcf081c5e7884ac05702bb5</gtr:id><gtr:otherNames>Kurowska-Stolarska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14749_19_19841166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB611411-1CFA-476F-9A25-3C27D75FEA67</gtr:id><gtr:title>Nitric oxide-induced regulatory T cells inhibit Th17 but not Th1 cell differentiation and function.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27d6c70628e2e918f4cbee0dcadac415"><gtr:id>27d6c70628e2e918f4cbee0dcadac415</gtr:id><gtr:otherNames>Niedbala W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14749_29_23720815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C81BAC6-3C3B-4E8C-9D3E-3CE6165E854C</gtr:id><gtr:title>An interleukin-33/ST2 signaling deficiency reduces overt pain-like behaviors in mice.</gtr:title><gtr:parentPublicationTitle>Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9610041be7243589a3de52ccc8754eb4"><gtr:id>9610041be7243589a3de52ccc8754eb4</gtr:id><gtr:otherNames>Magro DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0100-879X</gtr:issn><gtr:outcomeId>pm_14749_29_23903682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38F71884-ACCE-4A65-B059-33EE3C1A701B</gtr:id><gtr:title>Role of interleukin 33 in human immunopathology.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12deb286400a96352b1d739d0d0d7575"><gtr:id>12deb286400a96352b1d739d0d0d7575</gtr:id><gtr:otherNames>Murphy GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>oyyPEvcUWgD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CC386C0-C998-494F-BEB0-B3B750D98CDF</gtr:id><gtr:title>Interleukin-33 and the function of innate lymphoid cells.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76a9c296c0e07da4d0fb0e98d30823d5"><gtr:id>76a9c296c0e07da4d0fb0e98d30823d5</gtr:id><gtr:otherNames>Mirchandani AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn><gtr:outcomeId>pm_14749_29_22609147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5EB6EF5B-7144-4897-939D-AB26DB140314</gtr:id><gtr:title>Novel allergic asthma model demonstrates ST2-dependent dendritic cell targeting by cypress pollen.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bf4678bffdcb0cafd313bbf3b4880bb"><gtr:id>2bf4678bffdcb0cafd313bbf3b4880bb</gtr:id><gtr:otherNames>Gabriele L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>pm_14749_29_23608732</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9CD06C0-4BD0-4CF5-AD99-CB6FE80DC1EE</gtr:id><gtr:title>IL-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E2.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c67da887a938fbf22b16b3305eeaf91"><gtr:id>8c67da887a938fbf22b16b3305eeaf91</gtr:id><gtr:otherNames>Zarpelon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>pm_14749_29_23347081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE510BCC-D0DE-44B9-8860-31995A83A9FD</gtr:id><gtr:title>IL-15 mediates immune inflammatory hypernociception by triggering a sequential release of IFN-gamma, endothelin, and prostaglandin.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b16629f7643a0249636b4dc0eb514bb4"><gtr:id>b16629f7643a0249636b4dc0eb514bb4</gtr:id><gtr:otherNames>Verri WA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>C35DF473368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59D74107-8155-49B9-A108-ABC121308C59</gtr:id><gtr:title>Apolipoprotein E-deficient mice are resistant to the development of collagen-induced arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8c81b946dab25d016d4ae274f7b8944"><gtr:id>a8c81b946dab25d016d4ae274f7b8944</gtr:id><gtr:otherNames>Asquith DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>pFWg1h1tZcb</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601422</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>